APP and Alzheimer disease: Moreover, the expression of APP and MAPT—key proteins implicated in Aβ deposition and tau hyperphosphorylation—was significantly downregulated (p < 0.05 and p < 0.01, respectively), suggesting that the co-treatment may alleviate AD-related pathological protein accumulation (Table 4).